Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone949-284-4555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable
Evolus (NASDAQ:EOLS) Frequently Asked Questions
What is Evolus' stock symbol?
Evolus trades on the NASDAQ under the ticker symbol "EOLS."
How were Evolus' earnings last quarter?
Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings data on Monday, November, 4th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.55. The company earned $13.17 million during the quarter, compared to the consensus estimate of $5.18 million. View Evolus' Earnings History.
When is Evolus' next earnings date?
What price target have analysts set for EOLS?
8 Wall Street analysts have issued 1 year target prices for Evolus' stock. Their forecasts range from $13.00 to $37.00. On average, they expect Evolus' share price to reach $27.88 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View Analyst Price Targets for Evolus.
What is the consensus analysts' recommendation for Evolus?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.
What are Wall Street analysts saying about Evolus stock?
Here are some recent quotes from research analysts about Evolus stock:
- 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (10/15/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution and ahead of what we expect to be a better-than-expected launch of Jeuveau, we are reiterating our OW rating and 12-month price target of $35. We think Jeuveau’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the U.S. and other launches should drive EOLS’s stock higher, in our view." (4/30/2019)
- 3. HC Wainwright analysts commented, "We think investors understand that Evolus will offer discounts and rebates off the list price, but we have sensed continued confusion over what Evolus is trying to accomplish by setting its list price where it did. While inconsequential for our financial model, Evolus’ move reinforces a couple important elements of the company’s commercial strategy. Signaling to consumers. The Evolus story has evolved since David Moatazedi became CEO last spring. Before Moatazedi took over, Evolus’ message primarily focused on the opportunity to compete on price. However, we think this message undersold the company’s product, since it implied Jeuveau, then known as DWP-450, was no different than other lower-cost BoNT-A products already on the market, Merz’s Xeomin." (4/4/2019)
Has Evolus been receiving favorable news coverage?
Media stories about EOLS stock have been trending very negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evolus earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Evolus.
Are investors shorting Evolus?
Evolus saw a decline in short interest in October. As of October 15th, there was short interest totalling 3,900,000 shares, a decline of 10.3% from the September 15th total of 4,350,000 shares. Based on an average daily trading volume, of 358,600 shares, the days-to-cover ratio is currently 10.9 days. Approximately 23.9% of the company's shares are short sold. View Evolus' Current Options Chain.
Who are some of Evolus' key competitors?
Some companies that are related to Evolus include Nabriva Therapeutics (NBRV), Gossamer Bio (GOSS), Epizyme (EPZM), Zymeworks (ZYME), Innoviva (INVA), Enanta Pharmaceuticals (ENTA), Dicerna Pharmaceuticals (DRNA), BELLUS Health (BLUSF), Radius Health (RDUS), Supernus Pharmaceuticals (SUPN), Esperion Therapeutics (ESPR), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT), Theravance Biopharma (TBPH) and Y-mAbs Therapeutics (YMAB).
What other stocks do shareholders of Evolus own?
Who are Evolus' key executives?
Evolus' management team includes the folowing people:
- Mr. David Moatazedi, Pres, CEO & Director (Age 41)
- Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
- Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)
- Mr. Alejandro Sabad, VP of Operations
- Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury
When did Evolus IPO?
(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.
Who are Evolus' major shareholders?
Evolus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janney Montgomery Scott LLC (0.08%), Requisite Capital Management LLC (0.07%), Rhumbline Advisers (0.05%) and California Public Employees Retirement System (0.04%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Simone Blank and Vikram Malik. View Institutional Ownership Trends for Evolus.
Which major investors are selling Evolus stock?
EOLS stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Corp Alphaeon and Lauren P Silvernail. View Insider Buying and Selling for Evolus.
Which major investors are buying Evolus stock?
EOLS stock was bought by a variety of institutional investors in the last quarter, including Requisite Capital Management LLC, California Public Employees Retirement System and Rhumbline Advisers. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank and Vikram Malik. View Insider Buying and Selling for Evolus.
How do I buy shares of Evolus?
Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Evolus' stock price today?
One share of EOLS stock can currently be purchased for approximately $14.47.
How big of a company is Evolus?
Evolus has a market capitalization of $396.84 million. The company earns $-46,870,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Evolus employs 70 workers across the globe.View Additional Information About Evolus.
What is Evolus' official website?
How can I contact Evolus?
Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]
MarketBeat Community Rating for Evolus (NASDAQ EOLS)
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
